These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1820913)

  • 1. In vitro simulated pharmacokinetics profiles: forecasting antibiotic optimal dosage.
    Firsov AA
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():406-9. PubMed ID: 1820913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation of dose-antimicrobial effect in modeling in vitro pharmacokinetic profiles of normal and impaired elimination of antibiotics].
    Firsov AA
    Antibiot Khimioter; 1989 May; 34(5):375-8. PubMed ID: 2662928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dependence of the antimicrobial effect on the antibiotic concentration in modelling pharmacokinetic profiles in vitro: a comparison of 2 regimens for the single intravenous administration of sisomicin].
    Firsov AA; Chernykh VM; Fomina IP
    Antibiot Med Biotekhnol; 1987 Sep; 32(9):685-93. PubMed ID: 3324953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefotaxime kinetics in plasma and synovial fluid following intravenous administration in horses.
    Orsini JA; Moate PJ; Engiles J; Norman T; Poppenga R; Benson CE; Boston RC
    J Vet Pharmacol Ther; 2004 Oct; 27(5):293-8. PubMed ID: 15500566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics.
    Navashin SM; Fomina IP; Firsov AA; Chernykh VM; Kuznetsova SM
    J Antimicrob Chemother; 1989 Mar; 23(3):389-99. PubMed ID: 2659566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Principles for analyzing the kinetic curves of the antimicrobial effect in dynamic systems simulating the pharmacokinetic profiles of antibiotics].
    Firsov AA; Chernykh VM; Fomina IP
    Antibiot Med Biotekhnol; 1987 Feb; 32(2):122-9. PubMed ID: 3105433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.
    Firsov AA; Chernykh VM; Navashin SM
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1312-7. PubMed ID: 2117416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bactericidal effect of colistin on Escherichia coli. Model and simulation or the pharmacokinetic-pharmacodynamic relation for prediction of efficacy in veterinary antibiotic therapy].
    Renard L; Gicquel M; Laurentie M; Sanders P
    Vet Res; 1996; 27(1):23-32. PubMed ID: 8620185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A dynamic system for the in vitro study of the kinetics of the antimicrobial effect of antibiotics in pharmacokinetic changes in their concentration].
    Firsov AA; Chernykh VM; Kuznetsova SM; Navashin SM
    Antibiot Med Biotekhnol; 1985 Jan; 30(1):36-43. PubMed ID: 3888099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
    Buijk SE; Gyssens IC; Mouton JW; Metselaar HJ; Groenland TH; Verbrugh HA; Bruining HA
    J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose pharmacokinetics of cefodizime in critically ill elderly patients.
    Meyer B; Traunmueller F; Bojic A; Locker G; Schmid R; Winkler S; Thalhammer F
    Int J Antimicrob Agents; 2006 Apr; 27(4):335-8. PubMed ID: 16563704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sisomicin versus gentamicin. A comparison of antibacterial and pharmacokinetic properties (author's transl)].
    Naumann P; Rosin H; Reintjens E; Köhler M
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1277-84. PubMed ID: 782808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function.
    Huang V; Rybak MJ
    J Antimicrob Chemother; 2006 Jan; 57(1):116-21. PubMed ID: 16311369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NONMEM analysis in determining the tri-exponential disposition of cefotaxime: a method of evaluating serum and urinary phase I data.
    Weber W; Harnisch L; Zimmer M; Rokitta C; Mendes P
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):560-4. PubMed ID: 8574507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between mezlocillin and sisomicin in vitro and in patients with normal and various degrees of impaired renal function.
    Kampf D; Schurig R; Bergs A; Förster D
    Clin Nephrol; 1983 Jan; 19(1):37-44. PubMed ID: 6219847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of pharmacokinetics of cefotaxime in uranyl nitrate-induced renal damage in black bengal goats.
    Dutta BP; Debnath SC; Mandal TK; Chakraborty AK
    J Vet Sci; 2004 Mar; 5(1):1-3. PubMed ID: 15028879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with lower doses of cefotaxime in hospitalized patients with serious infections.
    Shah A; Madhavan T; Drelichman V; Price J
    J Chemother; 1989 Jul; 1(4 Suppl):650-1. PubMed ID: 16312575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.